Detalhe da pesquisa
1.
Adjunctive lumateperone (ITI-007) in the treatment of bipolar depression: Results from a randomized placebo-controlled clinical trial.
Bipolar Disord
; 25(6): 478-488, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-36779257
2.
Antidepressant effects of selective serotonin reuptake inhibitors (SSRIs) are attenuated by antiinflammatory drugs in mice and humans.
Proc Natl Acad Sci U S A
; 108(22): 9262-7, 2011 May 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-21518864
3.
Pharmacologic profile of ITI-333: a novel molecule for treatment of substance use disorders.
Psychopharmacology (Berl)
; 2024 May 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-38710856
4.
Single doses of a highly selective inhibitor of phosphodiesterase 1 (lenrispodun) in healthy volunteers: a randomized pharmaco-fMRI clinical trial.
Neuropsychopharmacology
; 47(10): 1844-1853, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35488084
5.
Safety and tolerability of lumateperone 42 mg: An open-label antipsychotic switch study in outpatients with stable schizophrenia.
Schizophr Res
; 228: 198-205, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33453691
6.
A review of the pharmacology and clinical profile of lumateperone for the treatment of schizophrenia.
Adv Pharmacol
; 90: 253-276, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-33706936
7.
Safety and tolerability of lumateperone for the treatment of schizophrenia: a pooled analysis of late-phase placebo- and active-controlled clinical trials.
Int Clin Psychopharmacol
; 36(5): 244-250, 2021 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34054112
8.
Efficacy and Safety of Lumateperone for Major Depressive Episodes Associated With Bipolar I or Bipolar II Disorder: A Phase 3 Randomized Placebo-Controlled Trial.
Am J Psychiatry
; 178(12): 1098-1106, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34551584
9.
Efficacy and Safety of Lumateperone for Treatment of Schizophrenia: A Randomized Clinical Trial.
JAMA Psychiatry
; 77(4): 349-358, 2020 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31913424
10.
Dopamine D2 receptor occupancy of lumateperone (ITI-007): a Positron Emission Tomography Study in patients with schizophrenia.
Neuropsychopharmacology
; 44(3): 598-605, 2019 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30449883
11.
Pharmacology of N-desmethylclozapine.
Pharmacol Ther
; 115(2): 223-31, 2007 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-17583355
12.
Antipsychotic-like behavioral effects and cognitive enhancement by a potent and selective muscarinic M-sub-1 receptor agonist, AC-260584.
Behav Neurosci
; 122(3): 570-5, 2008 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-18513127
13.
A 5-HT2A receptor inverse agonist, ACP-103, reduces tremor in a rat model and levodopa-induced dyskinesias in a monkey model.
Pharmacol Biochem Behav
; 90(4): 540-4, 2008 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-18534670
14.
Pharmacokinetics, tolerability, and safety of ACP-103 following single or multiple oral dose administration in healthy volunteers.
J Clin Pharmacol
; 47(6): 704-14, 2007 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-17473118
15.
PDE Inhibitors for the Treatment of Schizophrenia.
Adv Neurobiol
; 17: 385-409, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-28956340
16.
Dopamine Targeting Drugs for the Treatment of Schizophrenia: Past, Present and Future.
Curr Top Med Chem
; 16(29): 3385-3403, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-27291902
17.
ITI-007 for the Treatment of Schizophrenia: A 4-Week Randomized, Double-Blind, Controlled Trial.
Biol Psychiatry
; 79(12): 952-61, 2016 06 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-26444072
18.
Preclinical profile of ITI-214, an inhibitor of phosphodiesterase 1, for enhancement of memory performance in rats.
Psychopharmacology (Berl)
; 233(17): 3113-24, 2016 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-27342643
19.
Discovery of Potent and Selective Inhibitors of Phosphodiesterase 1 for the Treatment of Cognitive Impairment Associated with Neurodegenerative and Neuropsychiatric Diseases.
J Med Chem
; 59(3): 1149-64, 2016 Feb 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-26789933
20.
Effect Size and Blinding in Lumateperone Trial-Reply.
JAMA Psychiatry
; 77(6): 651-652, 2020 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32320025